Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Axonics Inc's Business Segments
Axonics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
SNM net revenue
Total Revenue
$ 116
Regions Reported
-
Revenue Share by Reportable Segment - FY
- SNM net revenue79.9%
- Bulkamid net revenue20.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| SNM net revenue | $ 92 | 79.9% |
| Bulkamid net revenue | $ 24 | 20.6% |
Revenue by Product & Service Category - FY
- Sacral Neuromodulation77.9%
- Bulkamid16.5%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Sacral Neuromodulation | $ 90 | 77.9% |
| Bulkamid | $ 19 | 16.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- SNM net revenue79.9%
- Bulkamid net revenue20.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| SNM net revenue | $ 92 | 79.9% |
| Bulkamid net revenue | $ 24 | 20.6% |
Description of Axonics Inc
Axonics Inc. is a medical technology company that develops and commercializes sacral neuromodulation systems for the treatment of urinary and bowel dysfunction. They are headquartered in Irvine, California, and operate globally.
Axonics' lead product, the Axonics Sacral Neuromodulation System, is a rechargeable implantable device that provides nerve stimulation to modulate the activity of the bladder and pelvic floor muscles. The device is implanted in the upper buttock area and connected to a lead that is positioned next to the sacral nerves. It is powered by a small, surgically-implanted battery that is designed to last up to 15 years. The device is controlled by a small, hand-held wireless programmer that allows patients to adjust the stimulation intensity and the frequency of the stimulation.
The Axonics system is designed to treat a range of clinical conditions, including overactive bladder, urinary retention, fecal incontinence, and chronic constipation. The system has been clinically proven to be safe and effective, with high success rates and low complication rates. Axonics received FDA approval in September 2019 for its sacral neuromodulation system for the treatment of patients with urinary dysfunction.
Axonics' mission is to provide patients suffering from urinary and bowel dysfunction with an alternative to traditional therapies such as medications and invasive surgeries. They focus on developing innovative technologies that are less invasive, more effective, and longer lasting than current treatments.
Axonics is committed to providing exceptional customer service and support to patients, healthcare providers, and their distribution partners. They have an experienced team of professionals dedicated to patient care and product development and are continuing to expand their global reach through regulatory approvals and partnerships.
Axonics' lead product, the Axonics Sacral Neuromodulation System, is a rechargeable implantable device that provides nerve stimulation to modulate the activity of the bladder and pelvic floor muscles. The device is implanted in the upper buttock area and connected to a lead that is positioned next to the sacral nerves. It is powered by a small, surgically-implanted battery that is designed to last up to 15 years. The device is controlled by a small, hand-held wireless programmer that allows patients to adjust the stimulation intensity and the frequency of the stimulation.
The Axonics system is designed to treat a range of clinical conditions, including overactive bladder, urinary retention, fecal incontinence, and chronic constipation. The system has been clinically proven to be safe and effective, with high success rates and low complication rates. Axonics received FDA approval in September 2019 for its sacral neuromodulation system for the treatment of patients with urinary dysfunction.
Axonics' mission is to provide patients suffering from urinary and bowel dysfunction with an alternative to traditional therapies such as medications and invasive surgeries. They focus on developing innovative technologies that are less invasive, more effective, and longer lasting than current treatments.
Axonics is committed to providing exceptional customer service and support to patients, healthcare providers, and their distribution partners. They have an experienced team of professionals dedicated to patient care and product development and are continuing to expand their global reach through regulatory approvals and partnerships.
Axonics Inc. is a forward-thinking medical technology company dedicated to enhancing the quality of life for individuals suffering from various chronic conditions primarily related to the nervous system. Focused on the development of innovative neuromodulation devices, Axonics targets treatment options for bladder and bowel dysfunction, sleep apnea, chronic pain, and a variety of other neurological disorders. The companys approach revolves around the core principle of neuromodulation, utilizing electrical impulses to modulate nerve activity and alleviate symptoms associated with debilitating conditions.
Segments
Axonics operates primarily within three significant segments:
1. Urology and Gynecology:
- In this segment, Axonics stands out as a pioneer in sacral neuromodulation, a therapeutic approach used primarily for treating urinary incontinence, fecal incontinence, and related conditions such as urinary retention.
- The flagship product, the Axonics System, is a rechargeable implantable neuromodulation device designed to restore control over bladder and bowel functions. The system is noteworthy for its long battery life (typically up to 15 years) and a minimally invasive implantation procedure, making it a favorable choice for patients relative to traditional, non-rechargeable devices.
2. Sleep Apnea:
- Following its acquisition of Contal Medical, Axonics expanded its portfolio into the domain of sleep disorders, particularly focusing on the treatment of obstructive sleep apnea.
- The range of implantable devices from Contal Medical is designed to stimulate the hypoglossal nerve, thereby influencing tongue and airway muscle functionality to prevent airway obstruction during sleep. This expansion has given Axonics the opportunity to address a significant public health issue, enhancing treatment options for individuals affected by sleep apnea.
3. Chronic Pain:
- Axonics is actively developing a spinal cord stimulation system aimed at providing an effective solution for patients experiencing chronic pain. This innovative system employs high-frequency stimulation techniques that differ from traditional spinal cord stimulation modalities, which may enable better pain control and reduce reliance on opioid medications.
Products and Services
Axonics provides a comprehensive array of products and services designed to cater to the diverse needs of patients and healthcare professionals:
1. Axonics System:
- The core of Axonics offerings, this rechargeable implantable neuromodulation device specifically targets conditions related to bladder and bowel dysfunction. The system facilitates a more practical approach for patients by eliminating the need for frequent device replacements and surgeries associated with disposable battery systems.
2. Contal Medical’s Implantable Devices:
- Under this umbrella, Axonics markets implantable devices that utilize electrical stimulation to control the signals that lead to airway collapse, thus improving breathing patterns during sleep and enhancing overall sleep quality for patients with obstructive sleep apnea.
3. Axonics SNM System:
- This device incorporates the principles of sacral neuromodulation specifically for the treatment of urinary and fecal incontinence. It aims to alleviate symptoms by modulating the signals in the sacral nerves associated with bladder and bowel control.
4. Spinal Cord Stimulation System:
- Currently under development, this novel system is expected to provide patients with chronic pain an innovative solution through advanced stimulation techniques that are designed to be more effective than standard therapies. It holds promise for enhancing patients quality of life while minimizing the use of pain medications.
5. Patient Education and Support Services:
- Axonics emphasizes the importance of patient engagement and education. Therefore, the company offers extensive educational materials and programs tailored to inform patients and healthcare professionals about the safe and effective use of their products. These services are intended to foster a better understanding of treatment options and empower patients towards better health outcomes.
Conclusion
Overall, Axonics Inc. is at the forefront of transforming the neuromodulation landscape through its cutting-edge products and services. By addressing significant health challenges linked to nerve-related disorders, the company is not only improving patient outcomes but also contributing to the evolution of medical treatment modalities in urology, sleep medicine, and pain management. The company’s ongoing commitment to innovation and patient care underscores its role as a leader in the healthcare technology industry, with a clear focus on enhancing the lives of individuals facing chronic health conditions.
Segments
Axonics operates primarily within three significant segments:
1. Urology and Gynecology:
- In this segment, Axonics stands out as a pioneer in sacral neuromodulation, a therapeutic approach used primarily for treating urinary incontinence, fecal incontinence, and related conditions such as urinary retention.
- The flagship product, the Axonics System, is a rechargeable implantable neuromodulation device designed to restore control over bladder and bowel functions. The system is noteworthy for its long battery life (typically up to 15 years) and a minimally invasive implantation procedure, making it a favorable choice for patients relative to traditional, non-rechargeable devices.
2. Sleep Apnea:
- Following its acquisition of Contal Medical, Axonics expanded its portfolio into the domain of sleep disorders, particularly focusing on the treatment of obstructive sleep apnea.
- The range of implantable devices from Contal Medical is designed to stimulate the hypoglossal nerve, thereby influencing tongue and airway muscle functionality to prevent airway obstruction during sleep. This expansion has given Axonics the opportunity to address a significant public health issue, enhancing treatment options for individuals affected by sleep apnea.
3. Chronic Pain:
- Axonics is actively developing a spinal cord stimulation system aimed at providing an effective solution for patients experiencing chronic pain. This innovative system employs high-frequency stimulation techniques that differ from traditional spinal cord stimulation modalities, which may enable better pain control and reduce reliance on opioid medications.
Products and Services
Axonics provides a comprehensive array of products and services designed to cater to the diverse needs of patients and healthcare professionals:
1. Axonics System:
- The core of Axonics offerings, this rechargeable implantable neuromodulation device specifically targets conditions related to bladder and bowel dysfunction. The system facilitates a more practical approach for patients by eliminating the need for frequent device replacements and surgeries associated with disposable battery systems.
2. Contal Medical’s Implantable Devices:
- Under this umbrella, Axonics markets implantable devices that utilize electrical stimulation to control the signals that lead to airway collapse, thus improving breathing patterns during sleep and enhancing overall sleep quality for patients with obstructive sleep apnea.
3. Axonics SNM System:
- This device incorporates the principles of sacral neuromodulation specifically for the treatment of urinary and fecal incontinence. It aims to alleviate symptoms by modulating the signals in the sacral nerves associated with bladder and bowel control.
4. Spinal Cord Stimulation System:
- Currently under development, this novel system is expected to provide patients with chronic pain an innovative solution through advanced stimulation techniques that are designed to be more effective than standard therapies. It holds promise for enhancing patients quality of life while minimizing the use of pain medications.
5. Patient Education and Support Services:
- Axonics emphasizes the importance of patient engagement and education. Therefore, the company offers extensive educational materials and programs tailored to inform patients and healthcare professionals about the safe and effective use of their products. These services are intended to foster a better understanding of treatment options and empower patients towards better health outcomes.
Conclusion
Overall, Axonics Inc. is at the forefront of transforming the neuromodulation landscape through its cutting-edge products and services. By addressing significant health challenges linked to nerve-related disorders, the company is not only improving patient outcomes but also contributing to the evolution of medical treatment modalities in urology, sleep medicine, and pain management. The company’s ongoing commitment to innovation and patient care underscores its role as a leader in the healthcare technology industry, with a clear focus on enhancing the lives of individuals facing chronic health conditions.